The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors
ESMO Gastrointestinal Oncology · Published 2026-07-23 · DOI 10.1016/j.esmogo.2026.100367
Free full text
Authors (22)
V. Sahai, Juan W. Valle, N. Fares, M. Javle, I. Ghanem, P. Cerdà, I.G. Rapposelli, I.G. Jimenez, M.A. Gonzalez-Carmona, A. Hollebecque, R. Pazo Cid, Daniel H. Palmer, R. Vera, A. Casadei-Gardini, D. Melisi, J.-F. Blanc, L. Perkhofer, Angela Lamarca, H. Gharbi, V. Manuel-Minguez, R. Robert, L. Rimassa
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Sahai, V., Valle, J., Fares, N., et al. (2026). The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors. ESMO Gastrointestinal Oncology. https://doi.org/10.1016/j.esmogo.2026.100367
Related articles
- Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Early-onset biliary tract cancers: clinical and molecular insights · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
- A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
- BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · ESMO Gastrointestinal Oncology · 2026 · Same journal
- Recent advances in loco-ablative therapies for liver cancers · ESMO Gastrointestinal Oncology · 2026 · Same journal